Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials

Highlights

• The pentavalent MenABCWY vaccine combining MenB-fHbp and MenACWY-TT components elicits broad serogroup-specific bactericidal immune responses comparable to licensed MenB-fHbp and MenACWY-CRM vaccines.
• Phase 3 non-inferiority trials show MenABCWY’s immunogenicity is consistent across both ACWY-naive and ACWY-primed adolescents and young adults with a favorable and comparable safety profile.
• Extended interval and booster studies demonstrate durable immune responses for up to 4 years and support flexible vaccination schedules.
• Co-administration with other vaccines and lot-to-lot consistency support operational feasibility for integration into adolescent immunization programs.